Comparison of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) with 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Phase III Clinical Trial
Background: The present study aimed to compare the rates of complete clinical and pathologic response to docetaxel, doxorubicin and cyclophosphamide (TAC) vs. 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) as neoadjuvant chemotherapy in women with locally advanced breast cancer.Methods: One...
Main Authors: | Mohammad Mohammadianpanah, Ahmad Mosalaei, Mansour Ansari, Niloofar Ahmadloo, Hamid Nasrolahi, Abdolrasoul Talei, Sedigheh Tahmasebi, Yaghoub Ashouri, Sare Hosseini, Shapour Omidvari |
---|---|
Format: | Article |
Language: | English |
Published: |
Shiraz University of Medical Sciences
2011-04-01
|
Series: | Middle East Journal of Cancer |
Subjects: | |
Online Access: | http://mejc.sums.ac.ir/index.php/mejc/article/view/50/135 |
Similar Items
-
Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial
by: Safa Najafi, et al.
Published: (2017-03-01) -
Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer
by: Wiseman Janice, et al.
Published: (2011-05-01) -
Quality of Life of Breast Cancer Women During Chemotherapy with Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) Regimen
by: Sophit Korpunsilp, et al.
Published: (2017-10-01) -
Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
by: Zhang MM, et al.
Published: (2016-06-01) -
Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer
by: Adeel M, et al.
Published: (2019-01-01)